Optimised beta blocker therapy in heart failure: is there space for additional heart rate control?

2012 ◽  
Author(s):  
Russell
Keyword(s):  
Heart Failure ◽  
Heart Rate ◽  
Beta Blocker ◽  
Rate Control ◽  
Heart Rate Control ◽  
Blocker Therapy ◽  
Beta Blocker Therapy

P3517Failure to achieve adequate heart rate control in women during therapy optimization

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
V Kutyifa ◽  
J W Erath ◽  
A Burch ◽  
B Assmus ◽  
D Bondermann ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Rate ◽  
Beta Blocker ◽  
Rate Control ◽  
Beta Blockers ◽  
Heart Rate Control ◽  
Blocker Therapy ◽  
Cardioverter Defibrillator ◽  
Beta Blocker Therapy ◽  
The Mean

Abstract Background Previous studies highlighted the importance of adequate heart rate control in heart failure patients, and suggested under-treatment with beta-blockers especially in women. However, data on women achieving effective heart rate control during beta-blocker therapy optimization are lacking. Methods The wearable cardioverter defibrillator (WCD) allows continuous monitoring of heart rate (HR) trends during WCD use. In the current study, we assessed resting HR trends (nighttime: midnight-7am) in women, both at the beginning of WCD use and at the end of WCD use to assess the adequacy of beta-blockade following a typical 3 months of therapy optimization with beta-blockers. An adequate heart rate control was defined as having a nighttime HR <70 bpm at the end of the 3 months. Results There were a total of 21,453 women with at least 30 days of WCD use (>140 hours WCD use on the first and last week). The mean age was 67 years (IQR 58–75). The mean nighttime heart rate was 72 bpm (IQR 65–81) at the beginning of WCD use, that decreased to 68 bpm (IQR 61–76) at the end of WCD use with therapy optimization. Women had an insufficient heart rate control with resting heart rate ≥70 bpm in 59% at the beginning of WCD use that decreased to 44% at the end of WCD use, but still remained surprisingly high. Interestingly, there were 21% of the women starting with HR ≥70 bpm at the beginning of use (BOU) who achieved adequate heart rate control by the end of use (EOU). Interestingly, 6% of women with adequate heart rate control at the start of therapy optimization ended up having higher heart rates >70 bpm at the end of the therapy optimization time period (Figure). Figure 1 Conclusions A significant proportion of women with heart failure and low ejection fraction do not reach an adequate heart rate control during the time of beta blocker initiation/titration. The wearble cardioverter defibrillator is a monitoring device that has been demonstrated in this study to appropriately identify patients with inadequate heart rate control at the end of the therapy optimization period. The WCD could be utilized to improve management of beta-blocker therapy in women and improve the achievement of adequate heart rate control in women.

scholarly journals Discharge heart rate and future events among Japanese patients with acute heart failure receiving beta-blocker therapy

2013 ◽  
Vol 03 (01) ◽  
pp. 159-167 ◽  
Author(s):  
Kazuki Oshima ◽  
Shun Kohsaka ◽  
Kimi Koide ◽  
Yuji Nagatomo ◽  
Toshiyuki Nagai ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Rate ◽  
Acute Heart Failure ◽  
Beta Blocker ◽  
Japanese Patients ◽  
Blocker Therapy ◽  
Beta Blocker Therapy ◽  
Future Events

Changes in Resting and Maximal Exercise Heart Rate during Dosing of Beta Blocker Therapy in Patients with Systolic Heart Failure

2008 ◽  
Vol 14 (6) ◽  
pp. S76-S77 ◽  
Author(s):  
Jalal K. Ghali ◽  
Ileana L. Pina ◽  
Jun R. Chiong ◽  
Daniel J. Lenihan ◽  
Lynne E. Wagoner ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Rate ◽  
Beta Blocker ◽  
Maximal Exercise ◽  
Systolic Heart Failure ◽  
Exercise Heart Rate ◽  
Blocker Therapy ◽  
Beta Blocker Therapy
Sign in / Sign up

Export Citation Format

Share Document